Hana Do, MPH

Real-world data is increasingly used to optimize trial design, reduce recruitment burden, and support regulatory decisions, but adoption remains uneven due to challenges around data quality, integration, and internal alignment across functional areas.

Analysis from the Tufts Center for the Study of Drug Development suggests that transparency in clinical evidence, community engagement, and more representative clinical trials are key factors associated with faster vaccine adoption and improved public trust.